Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, Japan, and China. This month’s report includes 8 biological drugs, 13 small molecules, 4 cell and gene therapies, 3 diagnostic tests and 5 devices
Genprex’ Reqorsa, focused on the treatment of SCLC, is the drug to receive ODD…
Shots:
The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March month
Darzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugs
The report summarizes the key features of Darzalex including revenue…
Shots:
Tania spoke about the Target the Future Think Tank Challenge and how it will advance and address key needs in the multiple myeloma
She also talked about GSK’s collaboration with the HealthTree Foundation to provide access, education, and support for underserved communities of multiple myeloma
The interview gives a profound understanding of how GSK…
Active Ingredients: Lenalidomide
Strength: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg
Dosage Form: Capsules
Mechanism of Action: Angiogenic inhibitor
First Approval: US (Dec 27, 2005), EU (14 Jun, 2007)
Revenue
Revlimid (lenalidomide) is one of the key products of Bristol-Myers Squibb (BMS) that represent a significant percentage of the company’s total revenue. Sales of…
In an interview with PharmaShots, Mark Wildgust, Vice President, Global Medical Affairs, Oncology at Janssen shared his views on the data of Imbruvica in P-III (GLOW) and P-II (CAPTIVATE) studies for the treatment of CLL or SLL and also highlighted the results of Darzalex in the P-II (GRIFFIN) & P-III (MAIA) study for multiple myeloma
The P-III (GLOW) and P-II (CAPTIVATE) studies evaluating Imbruvica + venetoclax (I+V) as a…
In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma community
Shots:
The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the community
A grant of…

